CA-ONCLUSIVE
5.1.2022 16:10:12 CET | Business Wire | Press release
Today, leading technology investor Symphony Technology Group “STG” completes its acquisition of Kantar ’s Reputation Intelligence business, and with it announces the additional purchases of PRgloo and Onclusive . Together the three businesses merge to create a new global media monitoring, measurement, and workflow management partner for PR and communications.
The new standalone company will operate under the name ‘Onclusive’ reflecting the inclusive and scalable nature of its newly combined offer and its commitment to accelerating investment in tech-powered platforms and solutions.
The company builds on the consultative strengths and scale of Europe’s largest media monitoring and analysis provider, Kantar Reputation Intelligence; UK-based PRgloo’s industry-leading media relations and workflow management platform and US-based Onclusive’s AI technology and data science.
Commenting on the new company, Chief Commercial Officer of the newly-formed Onclusive, Petra Masinova explained: “We’ve always admired each other’s strengths and we’ve increasingly teamed up on programmes to help solve clients’ needs. Today we accelerate our natural evolution to become one company, amplifying our strengths and supporting our clients with leading insights, technology and expertise together under one roof.”
Dan Beltramo, Chief Innovation Officer of the new Onclusive , also praised the union: “Onclusive is a technology and innovation pioneer in media monitoring and analytics while Kantar Reputation Intelligence is a leader in customer service with top-tier European coverage and market-leading insights capabilities. It brings us scale and ambition for global leadership.”
Samantha Deeks, VP Customer Experience at new Onclusive added: “Building on PRgloo’s customer-centric design approach, we’re delighted to work with like-minded industry leaders to build a scalable and agile business; one which actively listens and responds to the needs of its clients as they navigate an increasingly complex communications environment.”
Managing Director at STG, J.T. Treadwell , said: “Last year STG made clear its intention to create a market leading insights and software company through the proposed acquisition of Kantar Reputation Intelligence. Completing that acquisition is a major first step and the additional capabilities brought by Onclusive and PRgloo widen the scope of our commitment to providing best-in-class solutions for PR and Communications teams, both now and in the future.”
Onclusive will serve more than 9,000 clients, including many of the world’s biggest brands, across 130 markets. The company has over 1,100 employees based in the USA, UK, Ireland, France, Italy, Spain, Germany and Australia.
Onclusive North America Managing Director, Sean O’Neal , continued: “Our clients were our matchmakers – they told us they wanted one trusted partner to help them access and integrate our combined best-in-class services. We listened and from today Onclusive will help every client – from small enterprises to multi-national public and private organisations – shape, manage and evaluate their communications strategies.”
From today, clients can access the new Onclusive’s full range of services, supporting them at every stage of the communications cycle. Existing services continue uninterrupted.
About Onclusive
Onclusive is a global partner for PR and Communications success. We bring together Kantar Reputation Intelligence, the largest media monitoring and measurement service in Europe, with the best-in-class tools of PRgloo, and Onclusive’s own powerful AI and data science. Our technology, insights and expertise make sense of the fractured, fast-moving media world, helping you manage, monitor and measure your communications activity. Elevate your performance and prove and improve your value with Onclusive on your side.
About STG Partners
STG is a private equity partner to market leading companies in software, data analytics and software-enabled technology services sectors. The firm brings expertise, flexibility, and resources to build strategic value and unlock the potential of innovative companies. Partnering to build customer-centric, market leading portfolio companies, STG seeks to create sustainable foundations for growth that bring value to its companies. The firm is dedicated to transforming and building outstanding technology companies in partnership with leading management teams. STG and its predecessor, Symphony Technology Group (“Symphony”), have managed approximately $6 billion in total capital. For more information, please visit stgpartners.com
Kantar Reputation Intelligence – The leader in earned media tracking and measurement in Europe. Reputation Intelligence provides trusted insights on corporate, PR and brand coverage in 130+ markets to brands can understand and manage how audiences and influencers see them, globally and locally.
Onclusive – Empowers the world’s leading brands and agencies to modernize communications, increase performance and demonstrate value. The inventors of PR Attribution™ and Power of Voice™, Onclusive measures the true impact of earned, owned and social content on a company’s bottom line.
PRgloo – The complete media relations platform. PRgloo combines easy to use tools with exceptional analysis to make PR professionals’ lives easier by giving them the tools they need to do their jobs well.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005044/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom